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Abstract
Background: New HIV diagnoses related to injection drug use (IDU) have declined in the United
States. Access to clean syringes and decreasing HIV transmission among injection drug users have
been HIV prevention priorities of the Rhode Island (RI) HIV community. To examine trends in IDU-
related new HIV diagnoses in RI, we performed a retrospective analysis of new HIV diagnoses
according to HIV risk factor from 1990–2003.
Results: There has been an 80% absolute reduction in IDU-related new HIV diagnoses in RI
coincident with IDU-specific prevention efforts.
Conclusion: There has been a greater decline in IDU-related new HIV diagnoses in Rhode Island
compared to national data reported by the Centers for Disease Control and Prevention. We
hypothesize that this dramatic decline in Rhode Island is related to extensive HIV prevention efforts
targeting IDUs. Further research is needed to examine the impact of specific HIV prevention
interventions for injection drug users.
Background
Injection drug-use has been a major mode of HIV trans-
mission since the beginning of the HIV epidemic. How-
ever, in 2003, the Centers for Disease Control and
Prevention (CDC) reported a 42% decline in HIV diag-
noses among injection drug users (IDUs) from 1994–
2000 [1]. More recent surveillance data demonstrated a
4.1% decline in HIV diagnoses among IDUs from 2001–
2004 [2]. Recent studies in Baltimore and New York City
have documented a decline in HIV incidence among
injection drug users [3,4]. Factors that may contribute to
the observed decline in HIV diagnoses related to IDU
nationally include improved syringe access, improved
education and harm reduction efforts targeting IDUs, the
introduction of highly active antiretroviral therapy for the
treatment of HIV infection, and the decline may represent
the natural evolution of the HIV epidemic as the number
of susceptible IDUs shrinks. As demonstrated in the study
by Des Jarlais et al. in New York City, access to clean
syringes may impact HIV incidence among IDUs [4].
However, the ability of IDUs to obtain clean syringes var-
ies widely across the United States, largely based on the
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availability of syringe exchange programs and the ability
to legally purchase syringes via pharmacies [5].
In 1989, 50% of HIV cases in Rhode Island were associ-
ated with injection drug use [6]. In an effort to decrease
transmission of HIV between IDUs, prevention interven-
tions including syringe exchange programs, syringe pre-
scription programs, and legalization of syringe purchase
at pharmacies were developed and implemented in Rhode
Island from 1995–2000 [7-9]. The objective of this study
was to examine trends in new HIV diagnoses related to
injection drug use and other modes of transmission in
Rhode Island from 1990–2003, the time period during
which these IDU-related prevention interventions were
implemented. Trends were examined retrospectively by
reviewing the Rhode Island Department of Health HIV
database (State database) and the Miriam Hospital Immu-
nology Center database (Clinic database). We report a
dramatic decline in the number of new HIV diagnoses
attributed to injection drug use in Rhode Island coinci-
dent with the implementation of multiple HIV prevention
interventions targeting IDUs.
Results
According to the State database, which received HIV
reports anonymously from 1990–1999 and then via
unique identifier from 2000–2003, the number of new
HIV diagnoses declined from 685 (78% male, 22%
female) in 1990 to 134 in 2003 (77% male, 23% female).
The number of IDU-related new HIV diagnoses declined
from 365 in 1990 to 13 in 2003 (See Figure 1). The per-
centage of IDU-related new diagnoses in 1990 was 53%
and this declined to 9.7% in 2003, an absolute reduction
of 81%. Over the same time period, the percentage of new
diagnoses related to MSM transmission and heterosexual
transmission increased from 16% to 34% and from 4% to
19%, respectively.
According to the Clinic database, the number of newly
diagnosed persons entering care remained relatively sta-
ble with 58 persons entering care in 1990 and 65 persons
in 2003 (mean number of patients entering care per year
= 53). The percentage of IDU-related newly diagnosed
patients establishing care at the Clinic declined from 38%
in 1990 to 5% in 2003, an absolute reduction of 87%. The
percentage of new diagnoses related to MSM and hetero-
sexual transmission increased from 21% to 31% and from
24% to 55%, respectively. The percentage of IDU-related
new HIV diagnoses declined from 26% to 5% in males;
12% to 0% in females; 14% to 2% among Whites; 21% to
0% among Blacks; and increased from 2% to 3% among
Hispanics.
Conclusion
HIV infections secondary to injection drug-use have
declined across the United States. The reasons for this
decline are speculative however prevention programs tar-
geting IDUs have likely contributed. Nevertheless, close to
4000 new cases of HIV/AIDS due to injection drug use
were reported in 2004 suggesting that continued preven-
tion efforts are necessary [2]. Unfortunately, many states
still have strict laws and regulations prohibiting the pos-
session of syringes contributing to syringe reuse and shar-
ing among IDUs. Prevention efforts targeting IDUs have
been a priority in Rhode Island and have been imple-
mented through a multi-faceted approach over time. In
1994, Rhode Island authorized the opening of a syringe
exchange program in Providence. In 1998, the state legis-
lature reduced the penalty for possession of syringes from
a felony to a misdemeanor and in 2000, Rhode Island
passed legislation completely legalizing the sale of non-
prescription syringes by pharmacists.
The correctional system has also been an important site
for HIV prevention efforts targeting IDUs in Rhode Island.
The state correctional facility has been conducting routine
voluntary HIV testing upon entrance since 1991 and over
90% of all inmates are tested on incarceration [10].
Inmates who are identified as HIV-positive are linked to
HIV medical care and other programs such as Project
Bridge, a Ryan White CARE (Comprehensive AIDS
Resources Emergency) Act Special Project of National Sig-
nificance project aimed at maintaining continuity of med-
ical care upon release from the correctional setting [11].
This program includes substance use treatment including
linkage to methadone maintenance treatment in the com-
munity and intensive case management services for HIV-
positive ex-offenders. Furthermore, in Rhode Island, there
are six methadone maintenance treatment programs with
13 sites making this a widely available opiate replacement
option for IDUs.
There are limitations to this analysis. The decrease in IDU-
related new HIV diagnoses could be due to factors other
than the harm reduction programs described. For
instance, it is possible that the observed reduction is a
reflection of a finite population of IDUs in Rhode Island
being exposed to a new infectious disease to which they
are susceptible (in this case, HIV infection). Since the size
of the IDU population is relatively stagnant, the number
of persons susceptible to HIV declines as more persons
become infected. The introduction of highly active antiret-
roviral therapy in the late 1990's could have also led to
decreased transmissibility of HIV between IDU's which
may have led to a decrease in IDU-related HIV incidence.
Finally, the change in HIV reporting method in Rhode
Island from anonymous to unique identifier reporting in
2000 could have also contributed to the observed decline.Substance Abuse Treatment, Prevention, and Policy 2006, 1:34 http://www.substanceabusepolicy.com/content/1/1/34
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With anonymous testing, IDU's who are HIV-positive
would have been reported to the state anonymously each
time testing was completed. Repeat testing is common-
place in the correctional system. Once unique identifier
reporting was initiated, the potential for duplicate report-
ing would have been eliminated.
Nevertheless, our analysis reveals a greater than 80%
decline in the annual percentage of new HIV cases in the
state attributable to IDU over a 14-year time period. This
decline is twice as great as the decline observed by the
CDC in states with name-based HIV reporting. We
hypothesize the comprehensive HIV prevention efforts
targeting IDUs in Rhode Island are at least partially
responsible for this dramatic decline although direct cau-
sality cannot be determined from this study. Further
research is needed including comparisons of cities and
states with and without prevention interventions to deter-
mine the relative contribution of these programs in
decreasing the number of IDU-related new HIV infec-
tions. In addition, studies to investigate the effectiveness
of individual prevention interventions are needed to
guide future program implementation.
Methods
A retrospective analysis of two databases was performed
examining new HIV diagnoses according to risk category
[IDU, men who have sex with men (MSM), and heterosex-
ual] from 1990–2003. The data was obtained from the
Rhode Island Department of Health (State database) and
from The Miriam Hospital Immunology Center (Clinic
database), which is the largest outpatient HIV clinic in
Newly Diagnosed Cases of HIV Reported to the Rhode Island Department of Health by Year of Diagnosis Figure 1
Newly Diagnosed Cases of HIV Reported to the Rhode Island Department of Health by Year of Diagnosis. The 
number of newly diagnosed cases of HIV in Rhode Island and the number of new HIV diagnoses related to injection drug use 
from 1990–2003. The implementation of specific HIV prevention interventions targeting injection drug users is noted in boxes.
0
100
200
300
400
500
600
700
800
1990 1992 1994 1996 1998 2000 2002 2004
Year
N
o
.
 
o
f
 
C
a
s
e
s
Number New HIV Diagnoses Number New IDU-related HIV Diagnoses
Routine HIV Testing 
in Corrections
Needle 
Exchange
Syringe Possession:
Misdemeanor Offense
Legal Syringe Purchase 
and PrescriptionsPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Substance Abuse Treatment, Prevention, and Policy 2006, 1:34 http://www.substanceabusepolicy.com/content/1/1/34
Page 4 of 4
(page number not for citation purposes)
Rhode Island. When possible, new HIV diagnoses were
stratified by gender and race. This study was approved by
The Miriam Hospital Institutional Review Board.
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